$9m · Series A · Healthtech · Besançon, France
Besançon-based Archeon Medical, which makes real-time feedback devices for manual ventilation during cardiac arrest, has raised a $9m (€7.5m) Series A equity round. Newfund led the financing through its HEKA fund, with Eiffel Investment Group, UI Investissement's OSER BFC fund, Majycc Innovation Santé and Karot Capital participating. The company said the capital will fund US clinical validation and commercial scale-up of its EOlife system.
Clinical evidence is the next commercial milestone
Manual ventilation is one of the few parts of cardiopulmonary resuscitation that is commonly delivered without objective, real-time measurement. EOlife sits between the resuscitation bag and the patient, measuring the volume of air reaching the lungs and giving rescuers visual feedback so they can correct under-ventilation or hyperventilation. Archeon says the device is FDA-cleared and CE-marked and is already used in clinical and training settings.
The new financing is tied to a defined evidence programme rather than a new product launch. Archeon plans real-world studies covering more than 1,500 cardiac-arrest patients across Europe and the US, including work at Amsterdam UMC, Tualatin Valley Fire & Rescue EMS in Oregon and Rush University Medical Center in Chicago. The company expects results from the Tualatin Valley study in the first quarter of 2027, while the Rush study is expected to run longer.
That evidence has a direct commercial role. A feedback device can be cleared for sale and still face a slow adoption path if ambulance services and hospitals do not see enough clinical proof to change protocols, training and purchasing. Larger studies could strengthen Archeon's case for EOlife to be incorporated into emergency-care standards, while its reported OEM-partnership strategy offers a way to distribute the technology through established equipment manufacturers rather than relying only on a small direct sales team.
US scale-up starts from an existing foothold
Archeon was founded in 2018 by Alban De Luca and Pierre-Edouard Saillard. The company opened a US subsidiary in New York in 2024 after reporting that the market generated 60% of its revenue that year. Its official material names Johns Hopkins EMS Services, Palo Alto Fire Department, Stanford Children's Hospital and Rush University Hospital among US users, while a later company case study says Calhoun County EMS equipped its frontline ambulance fleet with EOlife.
The company now has 25 employees and reported $1.5m in 2025 revenue. For a small medical-device business, the round therefore has two linked jobs: fund the studies needed to support broader clinical adoption and build the commercial capacity to turn that evidence into repeatable US sales. Newfund's framing of ventilation as a brain-protection issue is material to that strategy, but the investment case still depends on the planned studies showing that measurable ventilation improves outcomes at scale.
